FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.
2 reports, 2 independent
Updated Aug 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Beam Therapeutics
American healthcare company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWS
- ZacksBEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate